Trial Profile
A Phase 1, First-in-Human, Multicenter, Open-label, Dose-escalation Study of IPH5201 as Monotherapy or in Combination With Durvalumab ± Oleclumab in Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 Mar 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; IPH 5201 (Primary) ; Oleclumab (Primary)
- Indications Adenocarcinoma; Pancreatic cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors AstraZeneca; MedImmune
- 23 Mar 2023 According to an Innate Pharma media release, data from this study were presented at the 2022 European Society for Medical Oncology I-O (ESMO Immuno-Oncology) Annual Congress in December.
- 01 Dec 2022 According to an Innate Pharma media release, data from this study will be presented at the 2022 European Society for Medical Oncology I-O (ESMO Immuno-Oncology) Annual Congress.
- 12 Aug 2022 Status changed from active, no longer recruiting to completed.